Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

TRK reported for 6 months of 2023 by RAS

7/28/23 TORS

Kaluga Sales Company reported for 6 months of 2023 by RAS

7/28/23 KLSB

Sakhalinenergo reported for 6 months of 2023 by RAS

7/28/23 SLEN

DIOD reported for 6 months of 2023 by RAS

7/28/23 DIOD

Magadanenergo reported for 6 months of 2023 by RAS

7/28/23 MAGE

Rosseti North-West reported for 6 months of 2023 by RAS

7/28/23 MRKZ

Acron reported for 6 months of 2023 by RAS

7/28/23 AKRN

Rosseti Moscow Region reported for 6 months of 2023 by RAS

7/28/23 MSRS

KuibyshevAzot reported for 6 months of 2023 by RAS

7/28/23 KAZT

Samolet's profit in first half of the year decreased by 5%

7/28/23 SMLT